DLBCL Market
Dec 19, 2022
ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges
The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL. Recently, off-the-shelf bispecific antibodies have grow...
Read More...
Dec 16, 2022
ASH 2022: Yescarta emerging as the CAR-T leader in DLBCL; Failure of Kymriah in early lines of DLBCL
CAR T-cell therapy is a type of immunotherapy that uses your body's white blood cells to fight your lymphoma. It uses a particular kind of white blood cell known as T lymphocytes or T cells. An essential part of CART therapies is lymphodepleting conditioning, which is administered to the patient before infusion of ...
Read More...
Jan 14, 2022
Most Promising Oncological Drugs Expected to Launch in 2022
The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
